ribosomal protein L18Genealiases: DBA18 · L18 · eL18
Q-omics provides the consensus-scored RPL18 profile across patient tissues and cancer cell-line models. RPL18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL18 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPL18 protein abundance shows 23,855 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RPL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL18 survival associations across molecular data types. RPL18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL18 RNA expression–survival associations across cancer types. High RPL18 expression shows unfavorable associations in ACC, LIHC, KIRP and SARC, but favorable associations in UVM and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL18 RNA expression.
This table summarizes RPL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL18 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, CHOL and LUSC. The KIRC box plot shows higher RPL18 RNA expression in tumor versus normal tissue (log2 FC = +1.043, t-test p < 0.001).
This table shows molecular features associated with RPL18 in patient tissues and cancer cell lines. In patient samples, RPL18 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
